Cytori Therapeutics (CYTX) Misses Q3 EPS by 2c

Cytori Therapeutics (NASDAQ: CYTX) reported Q3 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $2.85 million.

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

You May Also Be Interested In

• Nike (NKE) Tops Q1 EPS by 4c
• Kepler Cheuvreux Upgrades Interparfums SA (ITP:FP) to Buy
• Evercore ISI Upgrades Legrand SA (LR:FP) (LGRDY) to Outperform